by up to 76 per cent. Later, it also slashed prices of three generic cancer drugs -- Erlocip, Docetax and Capegard -- by up to 64 per cent.
The drug major also came out with an offer of USD 220 million (over Rs 1,200 crore) to acquire 51 per cent stake in South African firm Cipla Medpro.
Another Indian drug major, Sun Pharmaceutical Industries came out with an offer to buy Japanese drug maker Takeda Pharmaceuticals' US-based generics subsidiary URL Pharma, through its arm Caraco Pharma.
For the healthcare sector, 2012 turned out to be a period of expansion as it remained largely immune to the global economic slowdown.
Apollo Hospitals outlined its strategy for the year with plans to add 1,000 beds by the end of the 2012-2013. On the other hand Fortis Healthcare announced setting up of a 1,000 beds multi-speciality facility at an investment of Rs 450 crore. It will be operational in the next 2-3 years.
In July as part of strengthening its presence in the Singapore healthcare space, Fortis had opened a SGD 70 million (nearly Rs 308 crore) super speciality cancer hospital. Fortis sponsored Religare Health Trust (RHT) raised nearly SGD 510.7 million (about Rs 2,260 crore) by listing its units on the Singapore Exchange during the year.
Towards the end of the year, Fortis also announced that it would divest 64 per cent stake in Dental Corporation Holdings (DC), Australia to Bupa for 270 million Australian dollar (around Rs 1,554.36 crore) by March 2013.
Another major player, Max Healthcare also said it would add 600 beds in their existing hospitals by the end of the current financial year.
On the whole, for the pharmaceutical and healthcare sector, it was an action packed year with government's active steps standing out as highlights.